A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol.
A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol.
复制标题
在高密度脂蛋白胆固醇降低的非癫痫受试者中进行苯妥英的前瞻性随机试验。
DOI：
10.1161/01.atv.15.12.2151
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Garber,DW
中科院分区：
文献类型：
--
作者：
Miller,M;Burgan,RG;Osterlund,L;Segrest,JP;Garber,DW
Observational studies have demonstrated a positive association between phenytoin use and HDL cholesterol (HDL-C). Our goal was to determine whether phenytoin raises HDL-C in nonepileptic subjects at risk for coronary artery disease. We performed a double-blind, placebo-controlled, parallel-group study in 41 subjects with reduced levels of HDL-C. Subjects were placed on an American Heart Association Step I diet and were randomized to receive either phenytoin or placebo for 3 months. Serum levels of phenytoin were monitored and adjusted to between 7.5 and 15 μg/mL. Fasting levels of lipids and lipoproteins were determined twice at baseline (weeks −2 and −1) and during the treatment phase of the study (weeks 11 and 12). Compared with dietary baseline, phenytoin-treated subjects experienced significant paired percent increases in total HDL-C (12.4%;P<.01), an effect confined to the HDL2subfraction (137%;P<.01). The paired percent increases in HDL-C and HDL2levels remained significant after adjustment for placebo (P<.05,P<.025, respectively). There were no significant differences in the paired percent changes from dietary baseline in total cholesterol, triglyceride, or LDL cholesterol levels between placebo and phenytoin-treated groups. The significant paired percent increases in total HDL-C and HDL2from dietary baseline suggest a potential role for phenytoin in subjects with reduced levels of HDL-C.
